

Quality assurance of registers for Health Technology Assessment

Running title: Register data to inform technology assessment

Authors

Kate Mandeville
London School of Hygiene & Tropical Medicine

Maja Valentic
Croatian Institute of Public Health

Damir Ivankovic
Croatian Institute of Public Health

Ivan Pristas
Croatian Institute of Public Health

Jae Long
National Institute for Health and Care Excellence

Dr Hannah Patrick
National Institute for Health and Care Excellence

Corresponding author:
Dr Hannah Patrick
Centre for Health Technology Evaluation
National Institute for Health and Care Excellence
10 Spring Gardens, LONDON, SW1A 2BU, United Kingdom
Tel: +44(0)20 7045 2263 Mobile: +44(0)7572547370

Abstract

Objectives

To identify guidelines and assessment tools used by health technology agencies for quality assurance of registers and investigate the current use of register data by HTA organisations worldwide.

Methods

As part of a European Network for Health Technology Assessment Joint Action work package, we undertook a literature search and sent a questionnaire to all partner organisations on the work package and all organisations listed in the International Society for Pharmacoeconomics and Outcomes Research directory.

Results

We received 55 responses from organisations representing 21 different countries, a response rate of 40.5% (43/110). Many agencies – particularly in Europe - are already drawing on a range of registries to provide data for their HTA. Less than half, however, employ criteria or standards to assess the quality of registry data. Nearly all criteria or standards in use have been internally defined by organisations rather than referring to those produced by an external body. We identified thirteen relevant documents relating to quality assurance of registers. A comparison of internal and external standards identified consistency in several quality dimensions, which can be used as a starting point for the development of a standardised tool.

Conclusion

The use of register data is more prevalent than expected, strengthening the need for a standardised register quality assessment tool. A user-friendly tool developed in conjunction with stakeholders will support the consistent application of approved

quality standards, and reassure critics who have traditionally considered registry data to be unreliable.

Key words

Data quality, registers, evaluation

This work was funded by the European network for Health Technology Assessment, Joint Action 3, Work Package 5.

The authors are most grateful to all survey contributors.

There are no conflicts of interest to declare.

Introduction

The use of registers and registries is becoming increasingly common in health technology assessment (HTA) as interest grows in the use of observational data to complement experimental data and to accelerate the process of access to new technologies (1). Registries have been defined as “an organized system that collects, analyses, and disseminates the data and information on a group of people defined by a particular disease, condition, exposure, or health-related service, and that serves a predetermined scientific, clinical or/and public health (policy) purposes (2). The quality of registry data has often been criticised, however, leading to reluctance to embed their use in HTA (3-5). While there are several guides to improving observational data collection and reporting, there is no standardised tool for use by HTA agencies to assess registry quality (6-8).

The European network for Health Technology Assessment (EUnetHTA) has been working through a series of work packages of its Joint Action 3 (2016 – 2019; referred to as EUnetHTA JA3) to enhance the use of high-quality registries in HTA. The purpose of one of these work packages (Work Package 5 Strand B) is the production of a standardised tool for the use of registries in HTA, based on the “Methodological guidance on the efficient and rational governance of registries” (referred to here as the PARENT Guidelines) (2). The PARENT guidelines describe important dimensions in assessing the quality of registries, including governance, data quality, information quality and data protection (Table 1). The aim of the guidelines was to support EU Member States in developing comparable and interoperable patient registries in fields of identified importance (e.g. chronic and rare diseases, medical technology) with the aim to rationalise the development and governance of patient registries, thus enabling

Table 1: Recommendations for registries from the PARENT guidelines

Dimension	Subdimension	Criterion	Indicator(s)
GOVERNANCE	Procedures and methods for registry operation and governance	Clearly stated purpose, structures, protocol/ procedures and information governance policies	Registry manual
			Formal plan for registry governance and oversight covering overall direction and operations, scientific content, ethics, safety, data access, publications, and change management.
	Education and training	Registry staff as well as data providers should receive formal and refresher training on registry procedures	Training plan and record of training sessions
	Resource planning and financial sustainability	Resources should be adequate to ensure the sustainability, continual relevance and maximum impact of the data for which the registry holders are responsible	Registry size and duration defined
	Interoperability	Interoperability principles should be applied to all aspects of registry including establishment, development, operation, use and governance to support national and international collaboration	Use of semantic standards, models and tools
			Procedures for granting access to or sharing data (nationally or internationally) in place, including response time targets
	Self-assessment	Self-assessment should serve to identify sources of potential data quality issues and assess them by using indicators on data quality dimensions, developing measurements for evaluation, subsequently used to correct issues and track improvements (essentially data/quality improvement)	Formal audit and quality assurance plan
Establishment of a Quality Assurance Committee			
Expert guidance	The establishment of an Advisory Board consisting of a knowledgeable panel with expertise relevant to the registry domain and committed to the registry	Establishment of Advisory Board	
DATA QUALITY	Accuracy	How well information in or derived from the data reflects the reality it was designed to measure	Validity exercise against gold standard
	Completeness	Extent to which all necessary data that could have registered have actually been registered (coverage)	
	Interpretability and Accessibility	This includes the ease with which the existence of information can be ascertained, the suitability of the form or medium through which the information can be accessed, whether data are accompanied with appropriate metadata and whether information on their quality is also available (including limitation in use, generalisability and representativeness of registry)	Metadata and data dictionary available
			Membership of yellow-page type services like PARENT Joint Action Registry of Registries, AHRQ Registry of Patient Registries or other specialized “umbrella” registry
	Relevance	The degree to which data meet the current and potential needs of users	Stakeholder analysis
Timeliness	How current or up to date the data are at the time of release	Average gap between end of reference period for data and date available to users	

	Coherence	Coherence covers the internal consistency of data collection as well as its comparability both over time and with other data sources	Use of standard data definitions and a common data element to enable linkage
	Mode of data collection and impact on data quality	How well data collection is integrated into the working practice of data providers	Electronic data collection
			Minimal dataset Data collection template
INFORMATION QUALITY	-	The extent to which registry data are being used for their original purpose	Recent publications from registry data
			Data briefings/summary statistics available
			Establishment of Scientific Committee to guide scientific utilisation of registry data and assess external applications for utilisation of data
			Use of registry data in health service research/quality improvement/policies
DATA PROTECTION	-	The safeguards put in place to protect patient privacy and confidentiality	Information governance policy
		Registry adheres to Data Protection Directive (95/46/EC) or upcoming European Data Protection Framework	Privacy impact assessment

analyses of secondary data for public health, policy and research purposes in cross-border settings.

We present here the findings from the first part of this work package, namely (i) a literature review to identify any existing guidelines and/or assessment tools for quality assurance of registers, (ii) a survey to explore the current understanding and use of registries by HTA agencies and particularly the employment of any standards/criteria or other tool to assess the quality and comparability of registries before their use in HTA, and (iii) an overview of the registry quality dimensions in the standards/criteria identified through the literature review, researchers' prior knowledge and the survey. The purpose of the literature review, the survey and the overview of the guidance documents for registries was to feed into the development of a standardised tool to assess registries.

Methods

The National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) and the Croatian Institute of Public Health (HZJZ) led this study on behalf of EUnetHTA JA3. We conducted a literature search, using PubMed as the literature database and the following search terms were used (“technology assessment, biomedical”[MeSH Terms] OR (“technology”[All Fields] AND “assessment”[All Fields] AND “biomedical”[All Fields]) OR “biomedical technology assessment”[All Fields] OR (“technology”[All Fields] AND “assessment”[All Fields] AND “biomedical”[All Fields]) OR “technology assessment, biomedical”[All Fields]) AND (“registries”[MeSH Terms] OR “registries”[All Fields]). There were no date restrictions but only articles in English were reviewed. A single reviewer examined titles and abstracts in order to identify those that referred to the use of registries for health technology assessment.

An initial survey tool was developed based on discussions between NICE and HZJZ on the work programme objectives. Dimensions of registry use to be assessed in the survey included: the use of different types of registries by HTA organisations; the purposes for which registries were used in HTA; and the methodology and processes applied to assess quality of registries before use in HTA. Types of registries to be included in the survey were based on the PARENT Guidelines and defined as follows:

- Disease/condition registries (include patients with a common disease or condition e.g. cystic fibrosis or cancer)
- Pharmaceutical registries (include patients who have taken a particular pharmaceutical product)

- Medical technology registries (include patients who have been exposed to a particular device or diagnostic technology)
- Procedural registries (include patients who have undergone a particular medical or surgical procedure)

We specified purposes for which register data could be used by HTA agencies to reflect steps in the HTA process, namely:

- Natural history of disease/condition
- Evaluation of effectiveness (for example, data on the natural history of a disease/condition for decision modelling, or to create cohorts for comparative effectiveness analysis)
- Evaluation of cost and/or budget impact (for example, cost data from pharmaceutical registries, current and/or potential uptake of health technology from disease/condition registries)
- Future reviews of the technology, particularly where there is a lack of evidence for the technology (for example, safety/adverse events data from medical technology or procedural registries)

We asked whether HTA agencies used any standards or criteria to assess the quality of registries before use, and if so, whether these were defined internally by the organisation or an external organisation. If no standards were used, we asked whether other steps were taken to evaluate quality of register data before use in HTA.

The survey was conducted in English. Pre-testing of the survey tool was conducted among EUnetHTA JA3 members of NICE and HZJZ, with adjustments made to the

definitions of types of registries and the addition of a hyperlink to the PARENT wikipage on quality. A formal pilot of the survey was then conducted with two HTA organisations selected in order to ensure European and non-European representation, namely A Unidade de Asesoramento Científico-técnico (Avalia-t) in Spain and the Health Intervention and Technology Assessment Program (HITAP) in Thailand. Changes based on feedback from these organisations included the addition of a question on other methods to assess the quality of registries apart from quality standards, and revision of some wording to improve clarity for non-native English speakers. A final survey tool was developed to reflect these changes (see supplementary file 1).

The final survey tool was sent by email to all EUnetHTA JA3 partner organisations and all HTA organisations in the International Society for Pharmaco-economics and Outcomes Research (ISPOR) directory a total of 110 organisations (9). One reminder email was sent after two weeks to all organisations that had not yet responded. The survey was closed one month after the initial call.

Participants who reported using internal standards to assess the quality of registers were contacted up to three more times to request that they provide a copy of those standards for review. We compared the criteria listed in the external and internal standards obtained, to the recommendations of the PARENT project.

RESULTS

The literature review returned 96 titles and abstracts that met the inclusion criteria, from which we identified 22 relevant publications. The review identified no standards or guidelines specifically relating to the use of registries for HTA, however several described attributes of high quality registers which we discuss further below.

We received 55 responses to the survey from organisations representing 21 different countries, a response rate of 40.5% (43/110). One organisation was excluded as it does not undertake HTA (Semmelweis University Health Services Management Training Centre in Hungary). Two responses were received from six organisations: the Canadian Agency for Drugs and Technologies in Health (CADTH), Finnish Medicines Agency (FIMEA), Association of Austrian Social Insurance Institutions (HVB), Scottish Medicines Consortium, Belgian Health Care Knowledge Centre (KCE) and Swedish Dental and Pharmaceutical Benefits Agency (TLV). For these organisations, we used the first response received for analysis.

Responses were received from across Europe (see Figure 1 in the supplementary material on line). Agencies in Canada and Thailand also provided input. Responses were received from 33 out of a total 78 (42%) EUnetHTA partners. No responses were received from HTA organisations based in Latin America, Africa or Australasia.

Disease/condition registries were the most common type of registry used in HTA, with nearly three quarters of responding organisations using these registries compared to half or less using pharmaceutical, medical technology or procedural registries (Table 2). Other types of registries used in HTA included health expenditure databases such

as reimbursement or insurance data, pharmaceutical or medical technology wholesale data; clinical trials registries; and routine databases for usual care.

Table 2 Types of registers used in health technology assessment

Type of registry	Number of organisations using registry in HTA (%)
Disease/condition	30/41 (73.2)
Pharmaceutical	21/41 (51.2)
Medical technology	20/41 (48.8)
Procedural	17/41 (41.5)
Other	8/41 (19.5)

Effectiveness data and estimation of the current and/or potential uptake of a health technology were the two most common uses of registry data, with over two thirds of responding organisations employing registry data for these purposes (Table 3). Nearly two thirds of organisations were using registry data to estimate safety or adverse events. Registries were also being used by around one in two organisations to provide data on costs, the natural history of a disease or condition and cohorts for comparative effectiveness analysis. Other uses included assessment of comorbidities and patient characteristics for managed entry agreements and to monitor the appropriate use of pharmaceuticals post-launch.

Sixteen organisations report that they use criteria or standards to assess the quality of registry data before use in HTA. Most organisations used internally defined criteria or standards (14/16, 87.5%) with one organisation using both internally defined and external criteria/standards. Of the 14 organisations that reported using internally defined criteria, only two made these available to the study group (Italian Arthroplasty

Table 3 Use of registers in health technology assessment

Use of registry data	Number of organisations using registry data in HTA (%)
Effectiveness data	29/41 (70.7)
Current and/or potential uptake of health technology	29/41 (70.7)
Safety/adverse events data	27/41 (65.9)
Cost data	21/41 (51.2)
Natural history of disease/condition	20/41 (48.8)
Cohort data for comparative effectiveness analysis	19/41 (46.3)
Other	10/41 (24.4)

Registry and NICE). The Italian Arthroplasty Registry was excluded from further analysis as this was a review of data in the registry, rather than criteria for assessment of data quality. None of the organisations using internally defined register standards or criteria have published any assessments of registers using these tools.

For those organisations not employing criteria or standards to assess the quality of registry data, nearly one in two used discussion with experts (13/27, 48.1%) and one in three used discussion with stakeholders (9/27, 33.3%). One in five (6/27, 22.2%) inspected registry data directly before use in HTA. One organisation noted what information was lacking in existing registry studies. Another highlighted that there were no specific quality standards available for registries.

The literature review, researchers' prior knowledge and the survey, identified 13 guidance documents for registries (2,7-19); Methodological guidelines and recommendations for efficient and rational governance of patient registries (PARENT)

(2), Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices (FDA) (7), Recommendations for the development and operation of health-related registries (ANQ) (8), ISPOR Directory of HTA organisations worldwide (ISPOR) (9), Medical Device Registries - Six Key Principles (EUCOMED) (10), Evaluating databases - Interventional procedures programme (REBIP) (11), Principles of International System of Registries Linked to Other Data Sources and Tools (IMDRF) (12), Interventional procedures programme manual (NICE) (13) Registries for evaluating patient outcomes: A user's guide (AHRQ) (14), Operating Principles and Technical Standards for Australian Clinical Quality Registries (ACSQHC) (15), Data Quality, Validation and Data Source Integration in Rare Disease Registries (EPIRARE) (16), The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies (17), A Validated Checklist for Evaluating the Quality of Observational Cohort Studies for Decision-Making Support (GRACE Initiative) (18), Registry Studies: Why and How (19).

These publications differed in their scope (real world data sources vs. patient registries in general vs. specific type of patient registry), purpose (conducting vs. reporting vs. evaluating research), dimensions covered (design and conduct vs. quality dimensions such as governance, data quality and safety), or format (checklist vs. explanatory form). Three of the 13 guidance documents were excluded from further analysis because they focused on retrospective evaluation of design and conduct of a registry rather than prospective quality dimensions (17,18) or were based (19) on another guidance document (14). Table 4 provides a comparison of the included nine quality guidance documents against the dimensions described in the PARENT guidelines. For clarity, we have not provided the reference number of each corresponding criterion for each guidance, which are instead available in the supplementary online material

(along with summary details of each of the guidance documents in Suppl. Tables 1-12). Comparison is made against the PARENT guidelines, as these served as a starting point for the development of a standardised register quality assessment tool, for which this work acted as additional input. Table 4 shows wide variation in the criteria covered across all standards. Only the AHRQ standards covering all the quality dimensions outlined in the PARENT guidelines, with the internal NICE standards showing the fewest corresponding criteria. The most commonly mentioned areas across the guidelines are; Procedures and methods for registry operation and governance, Self-assessment, Data accuracy and completeness, Mode of data collection and impact on data quality, and Legal and ethical issues. With such consistency across guidelines, these areas could be viewed as essential quality criteria for education and training. Resource planning, Interpretable and accessible data, and Information quality (in terms of data briefings or recent publications) were omitted the most and could be viewed as optional quality criteria. . Interoperability, the key element to PARENT endeavours, was covered or explained in 6 of the 9 guidelines, and it is mostly presented as semantic or technical interoperability, rather than being described through all five interconnected levels as it stands in the European Interoperability Framework and PARENT guidelines.

Table 4 Comparison of PARENT recommendations with nine relevant published guidance documents

PARENT recommendations		Comparison with PARENT criterion (number of corresponding criterion)								
Dimension	Subdimension	NICE	Swiss standards	FDA	Eucomed	ReBIP	IMDRF	ACSQHC	AHRQ	EPIRARE
GOVERNANCE	Procedures and methods for registry operation and governance		X	X	X	X	X	X	X	X
	Education and training				X				X	
	Resource planning and financial sustainability		X		X	X		X	X	
	Interoperability		X		X		X	X	X	X
	Self-assessment		X	X	X	X	X	X	X	X
	Expert guidance	X	X			X	X	X	X	X
DATA QUALITY	Accuracy	X	X	X		X	X	X	X	X
	Completeness	X		X	X	X	X	X	X	X
	Interpretability and Accessibility			X			X	X	X	X
	Relevance	X	X	X				X	X	
	Timeliness			X				X	X	X
	Coherence		X	X			X	X	X	X
	Mode of data collection and impact on data quality		X	X	X		X	X	X	X
INFORMATION QUALITY	-		X			X	X	X	X	
CONFIDENTIALITY, SECURITY, PRIVACY, ETHICAL ISSUES, SECONDARY USE OF INFORMATION	-	X	X,N/A - EU regulation not applicable in Switzerland	X		X		X	X	X

DISCUSSION

This survey of HTA organisations shows that many agencies – particularly in Europe - are drawing on a range of registries to provide data for their HTA. Less than half, however, currently employ criteria or standards to assess the quality of registry data before use in HTA. Nearly all criteria or standards that are being used by HTA organisations have been defined by their organisation, rather than a standardised tool published by an external body. A comparison of internal and external standards identified wide variation in content. However there was consistency in several quality criteria, which can be used as a starting point for development of a standardised tool.

Registries have been recognised as an important source of data and information, both during the pre- as well as post-launch phases of technology lifecycle and related assessments, yet until now, only anecdotal evidence was available on the use of registries by HTA organisations in Europe (10,11). Contrary to expectations, this survey shows that HTA organisations are actively using registry data for complex decision-making in a range of areas but without reference to a standardised method to assess relevance and quality. Given that the use of registries is more prevalent than expected, this strengthens the need for a standardised tool to promote best practice for the collection and use of such data.

The survey also identified a number of criteria/standards currently in use by HTA organisations. We were only able to obtain one example of internal standards in use, despite concerted follow-up. It is possible that the internal 'definition' of standards was not formalised and in an easily sharable form, which again supports the need for an accessible and rigorous tool. The challenge is to apply such standards consistently to

ensure that only registry data of sufficient relevance and quality influences decision-making. A previous audit of registries using the NICE internal standards found that the quality of recommended registers was disappointing, with only a few registers mature enough to deliver evidence of sufficiently high quality to inform funding decisions (20). The NICE internal standards were found to be more limited than external guidelines in terms of quality criteria, which may have contributed to this result.

Our comparison of internal and external standards provides a good starting point for the development of an internationally recognised, user-friendly tool that can be used across jurisdictions. Such a tool developed in conjunction with EUnetHTA stakeholders will support consistency of application, as well as reassure critics who have traditionally considered registry data to be unreliable for use in HTA. Collaboration in development of such a tool will be essential in order to achieve agreement around the application of terminology. For instance “completeness” is considered by many to be a criterion that needs to be evaluated in the context of a register’s purpose, recognizing that a register may attempt to collect broad data to meet the interests of all stakeholders but not all may be essential to the purpose of HTA. The initiative must also recognise that data quality assessment and management for evidence generation is highly topical currently and should learn from other relevant work e.g. ‘Data Curation’ covers many of the principles that the tool should include. It has been defined as “the active and ongoing management of data through its life cycle of interest and usefulness to scholarship, science, and education. Data curation activities enable data discovery and retrieval, maintain its quality, add value, and provide for reuse over time, and this new field includes authentication, archiving, management, preservation, retrieval, and representation” (21).

Strengths of this research include the comprehensive piloting of the survey tool to ensure common interpretation among non-native English speakers. Despite this, it is possible that the survey was subject to variation and overlap in use of terms such as disease/pharmaceutical register. We included purposes of register data specific to the needs of HTA agencies, i.e. organisational (uptake), technological (effectiveness) or economical (cost) evaluation clusters, however it is possible that registers were being used for other purposes not picked up as relevant to this survey, e.g. epidemiological. Any standard developed will need to reflect the diverse current use of registers in HTA.

The comprehensive distribution list used for the survey strengthened the methodology, but may have contributed to a fairly low response rate of 40%. Translation of the survey tool into other languages such as Spanish may have increased participation, for example from Latin American HTA agencies. Thus the results presented here should be seen as only an indicative picture of the relationship between HTA activity and registries. An alternative methodological approach, rather than identifying quality standards already in use, would have been to build consensus on those registers that are considered to produce high quality data and then to examine features that the corresponding registries had in common. However, many registers only capture data from one jurisdiction and therefore it seemed likely that these features would be already captured in jurisdiction-specific quality standards.

In conclusion, many HTA agencies are already using register data, despite the lack of a standardised quality assessment tool. A review of existing standards found wide variation in content, but some consistency in included and omitted criteria. These

findings will be taken into consideration during the development of the EUnetHTA registries for HTA tool.

References

1. Accelerated Access Review: Final Report. Review of innovative medicines and medical technologies. 2016. London: Available from:
<https://www.gov.uk/government/organisations/accelerated-access-review> (accessed 2017 Dec 6th)
2. Zaletel M, Kralj MM (Eds). Methodological guidelines and recommendations for efficient and rational governance of patient registries. 2015. National Institute of Public Health, Ljubljana. Available from:
https://ec.europa.eu/health/sites/health/files/ehealth/docs/patient_registries_guidelines_en.pdf (accessed 2018 Mar 12th)
3. Devices Sanket S, Dhruva, Lisa A, Bero, Rita F, Redberg. Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular JAMA. 2009;302(24):2679-2685.
4. Wilkinson J, Crosbie A. A UK medical devices regulator's perspective on registries. Biomed Tech (Berl) 2016 Apr 1;61(2):233-7.
5. Smeeth L, Douglas I, Hubbard R. Commentary: we still need observational studies of drugs--they just need to be better. Int J Epidemiol 2006 Oct;35(5):1310-1.
6. Glynn D, Campbell B, Marlow M, Patrick H. How to improve the quality of evidence when new treatments are funded conditional on collecting evidence of effectiveness and safety. J Health Serv Res Policy 2016 Apr;21(2):71-2.
7. U.S. Department of Health and Human Services Food and Drug Administration (FDA). Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff [Internet]. Rockville (MD): FDA; 2017. Available from:
<https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocument/ucm513027.pdf> (accessed 2017 Dec 6th)
8. ANQ, FMH, H+, SAMS, University Medicine Switzerland. Recommendations for the development and operation of health-related registries [Internet]. Switzerland; 2016. Available from:
http://www.anq.ch/fileadmin/redaktion/deutsch/20160926_Empfehlungen_Register_final_en.pdf (accessed 2017 Dec 6th)
9. ISPOR Directory of HTA organisations worldwide Available from:
<https://www.ispor.org/htadirectory/index.aspx> (accessed 2017 Dec 6th)
10. Eucomed. Medical Device Registries: Six Key Principles [Internet]. Brussels: Eucomed; 2016. Available from:
http://www.medtecheurope.org/sites/default/files/resource_items/files/Registries%20for%20Medical%20Devices%20in%20Europe%20Reflection%20Paper_January%202016.pdf (accessed 2017 Dec 6th)
11. Review Body for Interventional Procedures Programme (ReBIP). Evaluating Databases [Internet]. 2005 [cited 2017 Oct 4]. Available from:

- https://www.sheffield.ac.uk/polopoly_fs/1.43797!/file/Evaluating-Databases-15-March-2006.pdf
(accessed 2017 Dec 6th)
12. IMDRF Patient Registries Working Group. Principles of International System of Registries Linked to Other Data Sources and Tools 2016. Available from:
<http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-160930-principles-system-registries.pdf>
(accessed 2017 Dec 6th)
 13. National Institute for Health and Clinical Excellence. Interventional procedures programme manual NICE; 2016. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK425827/> (accessed 2017 Dec 6th)
 14. Agencies for Healthcare Research and Quality (AHRQ). Registries for evaluating patient outcomes: A user's guide. Available from: https://ahrq-ehc-application.s3.amazonaws.com/media/pdf/registries-guide-2nd-edition_research.pdf (accessed 2018 Mar 13th)
 15. Australian Commission on Safety and Quality in Health Care. Operating Principles and Technical Standards for Australian Clinical Quality Registries. Available from:
<https://www.safetyandquality.gov.au/our-work/information-strategy/clinical-quality-registries/testing-and-validating-the-draft-operating-principles-and-technical-standards-for-clinical-quality-registries/>. (Accessed 2018 Mar 13th)
 16. Posada M et al. Data Quality, Validation and Data Source Integration in Rare Disease Registries. WP 7 deliverable EPIRARE project; 2014. Available from:
http://www.epirare.eu/download/D4_GuidelinesfordatasourcesandqualityforRDRegistriesinEurope.pdf (accessed 2017 Dec 6th).
 17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol.* 2008 Apr;61(4):344-9. DOI: 10.1016/S0140-6736(07)61602-X.
 18. GRACE: Good ReseArch for Comparative Effectiveness. A Validated Checklist for Evaluating the Quality of Observational Cohort Studies for Decision-Making Support. Available from:
<http://www.graceprinciples.org/doc/GRACE-Checklist-031114-v5.pdf> (accessed 2017 Dec 6th)
 19. CDG Whitepapers. Registry Studies: Why and How Available from:
http://clinicaldevice.typepad.com/cdg_whitepapers/2011/07/registry-studies-why-and-how.html.
(accessed 2017 Dec 6th)
 20. Mandeville KL, Patrick H, McKenna T, Harris K. Assessing the quality of health technology registers for national guidance development. *Eur J Public Health.* 2017 Sep 12. doi: 10.1093/eurpub/ckx135.
 21. CLIR. What is data curation. Available from <https://www.clir.org/initiatives-partnerships/data-curation/> (accessed 2018 Feb 28th)